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Background: Enhanced glycolysis is observed during tumorigenesis, with an upregulation in key glyco-
lytic enzymes. Hexokinase II (HKII) catalyzes the ﬁrst irreversible step of glycolysis and is often over-
expressed in tumors. Abnormal vasculature within tumors leads to regional ischemic conditions that
promote tumor progression. The aims of this study were to assess the expression of HKII in colorectal
cancer tissues, and to correlate HKII expression with clinical parameters and patient outcome.
Materials and method: Sections from 60 FFPE primary colorectal cancer tumor samples were dual
ﬂuorescence immunostained for HKII and carbonic anhydrase IX (CAIX; serving as an ischemic marker)
and assessed using semi-quantitative immunoﬂuorescence. Associations of HKII and CAIX levels with
patient characteristics, tumor pathology and clinical outcome were studied using univariate analysis.
Results: HKII expression was found in neoplastic cells of non-ischemic regions of tumors and within the
tumor stroma. CAIX expression was found primarily in neoplastic cells, and was associated with patient
age (OR¼4.04, Z70 vs. o70). Tumor samples scoring lower for HKII were associated with early disease
progression (p¼0.0155) and poor overall survival (p¼0.0248). Interestingly, tumor samples that pre-
sented with stromal HKII staining were associated with early disease progression (p¼0.0485) and poor
overall survival (p¼0.0235).
Conclusion: We identiﬁed low overall HKII expression to be associated with the outcome of colon cancer.
However, the correlation between stromal HKII expression and worse survival in colorectal cancer pa-
tients warrant further investigation.
MicroAbstract: This study assessed the prognostic value of hexokinase II expression in colorectal cancer.
In total, 60 FFPE primary colorectal cancer tumor samples were immunostained and correlated with
patient characteristics, tumor pathology and clinical outcome. Interestingly, low overall HKII expression
was correlated with worse patient outcome. Separately, stromal HKII staining was correlated with worse
patient outcome.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-
related deaths in the United States and the third most common
cancer in men and in women. In 2015, it was estimated that CRC
would account for 17.6% of all new cancer cases and 25.3% of all
cancer-related deaths [1]. Decreasing mortality rates have been
attributed to early screening, reduced prevalence of risk factors,
and/or improved treatments [2,3]. However, outcome for patients
with advanced and metastatic disease remains poor.
In 2011, deregulating cellular energetics was identiﬁed as an
emerging hallmark of cancer [4]. Many tumors upregulate key
glycolytic enzymes of the glycolytic pathway for energyLtd. This is an open access article uproduction regardless of oxygen tension in a phenomenon called
the Warburg effect [5], and studies have correlated the glycolytic
state of cancer cells with tumor aggressiveness [6]. Therefore,
speciﬁc glycolytic enzymes may serve as possible biomarkers of
CRC aggressiveness, providing useful prognostic tools.
The family of hexokinase (HK) enzymes function to catalyze the
ﬁrst irreversible step of glycolysis in which glucose is phosphory-
lated to glucose-6-phosphate. HKII expression is normally limited to
insulin-sensitive tissues [7]. However, upregulation of HKII is con-
sidered a consequence of metabolic re-programming in cancer, and
has been shown in breast carcinoma [8], laryngeal squamous cell
carcinoma [9], glioblastoma multiforme [10], and gastric adeno-
carcinoma [11]. Its assessment in CRC has been limited; im-
munohistochemical analyses on 104 surgically resected CRC sam-
ples showed a positive correlation between HKII expression with
extensive tumor diameter, advanced tumor depth, the presence of
lymph node metastasis, and shorter recurrence-free survival [12].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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morigenesis leads to ischemic regions within solid tumors [13].
Cells within these regions are exposed to poor blood ﬂow leading
to transient or chronic hypoxic and hypoglycemic conditions. HKII
expression is upregulated under hypoxic conditions as a result of
stabilized HIF-1α transcription factor [14]. Carbonic anhydrase
nine (CAIX) catalyzes the hydration of carbon dioxide to bicarbo-
nate and proton [15]. CAIX is a HIF-inducible gene used as an is-
chemic marker and is overexpressed colorectal cancer [16,17].
In this study, we evaluated the expression of HKII and CAIX in
formalin-ﬁxed parafﬁn-embedded (FFPE) specimens of CRC tu-
mors and assessed its relationship to patient outcome. Based on
ﬁndings from other studies, we hypothesized that high HKII ex-
pression would be associated with shorter progression-free status
and worse outcome.2. Materials and methods
2.1. Samples
Sixty FFPE CRC samples used for this study were gathered by
the Ontario Tumor Bank, Ontario Institute for Cancer Research,
Toronto, ON. Samples were collected between 2005 and 2011. The
patients' medical records were reviewed and general information,
including sex, age range at diagnosis, histological grade, and TNM
staging [18], are provided in Table 1. Follow-up data were re-
trieved for survival analysis. The last follow-up was May 2013.
Cases were anonymized and the researchers were blinded to tu-
mor and patient details until completion of image capture and
analysis.
2.2. Cell lines and immunoblot analysis
Human colorectal cancer cell lines HCT116 and DLD-1 were
obtained from ATCC (Manassas, VA, USA) and were maintained in
high glucose DMEM (Sigma-Aldrich, Oakville, ON, Canada) sup-
plemented with 10% FBS (Life Technologies, Grand Island, NY, USA)
and incubated at 37 °C in a humidiﬁed atmosphere containing 5%
CO2 in room air. Anoxic conditions were achieved using a Modular
Incubator Chamber (Billups-Rothenberg Inc., Del Mar, CA, USA)
modiﬁed to allow continuous ﬂushing of the chamber with a hu-
midiﬁed mixture of 95% N2 and 5% CO2. Cell lysates were subjected
to SDS-PAGE followed by western blotting with rabbit anti-HKII
(2867; 1:5000; Cell Signaling Technology) and mouse anti-CAIXTable 1
Patient characteristics.
Variable N %
Sex
Male 34 57
Female 26 43
Age at diagnosis (years)
o70 31 52
Z70 29 48
Histological grade
I 5 8
II 25 42
III 19 32
IV 9 15
Not available 2 3
AJCC-TNM stage
1 2 3
2 16 27
3 20 33
4 13 22
Not available 9 15(ab107257; 1:1000; Abcam plc, Cambridge, UK). Bands were de-
tected with HRP-conjugated goat anti-rabbit or anti-mouse anti-
bodies (1:10000; Sigma-Aldrich) using Luminata Forte chemilu-
minescent substrate (Millipore, Billerica, MA, USA).
2.3. Immunoﬂuorescence staining
FFPE histological sections were deparafﬁnized in xylene, rehy-
drated in isopropanol, and antigen retrieval was performed with
heated sodium citrate buffer (pH 6.0). Sections were blocked with
1:1 solution of 5% goat serum in PBSþ0.1% Tween (PBST) and
protein block solution (Dako, Denmark) followed by overnight
incubation at 4 °C with rabbit mAb HKII (2867, 1:400, Cell Sig-
naling Technology, Davers, MA) and mouse mAb CAIX (ab107257,
1:400, Abcam plc, Cambridge, UK). Sections were washed then
incubated with goat anti-rabbit Alexa 488-conjugated (1:300, Life
Technologies, Carlsbad, CA) and goat anti-mouse Cy3-conjugated
(1:200, Life Technologies) antibodies. Slides were counterstained
with DAPI, mounted with Fluorescence Mounting Media (Dako)
and stored ﬂat in the dark at 4 °C.
2.4. Imaging and quantiﬁcation of immunoﬂuorescence
Images of slides stained with HKII and CAIX antibodies were
captured with a QICAM camera (QImaging, BC, Canada) using a
40 objective lens. Files were captured at 1.4 megapixel resolu-
tion, using excitation and barrier ﬁlter sets for ﬂuorescein (green
emission), rhodamine (red emission) and DAPI (blue emission). In
total, 5 images were captured per slide, covering different regions
of the sample in an unbiased, systematic fashion. Fiji [19] was used
to process and analyze the images to determine HKII and CAIX
staining. For CAIX staining in all images, a minimum threshold
value of 20 was used in the software and the percent area stained
was subsequently calculated. A variation of the semi-quantitative
H-Score immunohistochemistry evaluation method [20] was used
to assess HKII staining, and given the term “F-Score”:
F-Score¼(% area stained at threshold¼25)þ(% area stained at
threshold¼85).
2.5. Statistical analysis
GraphPad Prism software v6.0 (GraphPad Software Inc., La Jolla,
CA, USA) was used for statistical analysis. Correlations between
staining parameters and patients' characteristics were analyzed
with Fisher's exact test. Progression-free survival (PFS) and overall
survival (OS) were calculated per the Kaplan–Maier method and
were compared between two groups by using the logrank test.
Patients lost to follow-up, and those still progression-free and/or
still alive at last follow-up were right-censored for survival ana-
lysis. Results were considered signiﬁcantly different when a two-
sided p value r0.05 was achieved.3. Results
3.1. Patient characteristics
Clinicopathological characteristics of the study cohort are
shown in Table 1. Brieﬂy, there were slightly more men (N¼34,
57%) than women in this study. The cohort contained both low-
grade (I and II; N¼30, 50%) and high-grade (III and IV; N¼28, 47%)
tumors, while for 2 cases the grading was not available. Seventy-
ﬁve percent of patients presented with early (stage 1, 2 or 3;
N¼38) AJCC-TNM tumors while 25% presented with late (stage 4;
N¼13) AJCC-TNM tumors. AJCC-TNM stage was not available for
15% (N¼9) of the cases.
Fig. 1. HKII and CAIX immunodetection in colorectal cancer cell lines and samples. (A) HKII and CAIX expression was detected by western blot analysis in two human CRC
cell lines. Cells were exposed to either normoxia (C; 20% O2) or anoxia (A;o0.1% O2) for 24 h. (B) Immunostaining for HKII (green), CAIX (red), DAPI nuclear counterstain
(blue), and merged images. Scale bar¼20 μm. CAIX was used as a marker of ischemia. The top panels show images from a non-ischemic region of a tumor sample and the
bottom panels show images from an ischemic region of a different tumor sample. (C) Immunoﬂuorescent staining of HKII and corresponding F-Scores. Images were taken at
40 objective. Scale bar¼50 μm. Images in the top panel with a F-Score ofo25 were considered to have a low F-Score. Images in the bottom panel with a F-Score of425
were considered to have a high F-Score. Arrows in panel (v) indicate stromal cell staining. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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CAIX
Human colorectal cancer cells showed an upregulation in both
HKII and CAIX expression following 24 h anoxic exposure in vitro
(Fig. 1A). IF revealed heterogeneous staining for both HKII and
CAIX in FFPE sections of human CRC; representative staining pat-
terns are shown in Fig. 1B. Both markers were localized to the
cytoplasm in neoplastic cells. HKII staining was predominantly
located in areas of low CAIX, suggesting HKII expression is pri-
marily present in non-ischemic regions of the tumors (Fig. 1B).
Computational analysis was used to examine both CAIX and
HKII staining. The median area stained for CAIX after analysis was
15.5% with a minimum of 1.3% and maximum of 65.5%, and this
median value was used to dichotomize the cases into ‘low’ and
‘high’ for subsequent evaluation. For HKII staining the F-Score was
obtained by the summation of percent area HKII staining at two
minimum thresholds, of 25 and 85. The median F-Score was 24.7
with a minimum of 3.4 and maximum of 71.5. This median F-Score
was used to dichotomize the cases into ‘low’ and ‘high’.Fig. 2. Progression-free survival and overall survival by CAIX and HKII staining. Kaplan
staining. (B) PFS and OS in patients with CRC based on HKII staining. (C) PFS and OS in pa
censored subjects. HR¼hazard ratio as calculated by logrank analysis.3.3. Association of CAIX and HKII expression with patient
characteristics
Age was signiﬁcantly associated with ‘high’ CAIX expression
(p¼0.012; OR¼4.04, Z70 vs. o70), but there were no signiﬁcant
associations with CAIX expression and sex, histological grade, TNM
stage, or primary tumor size (pZ0.05). HKII expression was not
statistically associated with sex, age at diagnosis, histological
grade, TNM stage, or primary tumor size (pZ0.05).3.4. Association of CAIX and HKII expression with patient outcome
No signiﬁcant differences in PFS or OS were observed
between patients with low CAIX expression and those with high
expression (PFS p¼0.1596; OS p¼0.0845; Fig. 2A), although
both PFS and OS trended towards better outcome with low CAIX.
High HKII expression was signiﬁcantly associated with im-
proved outcome of CRC patients (PFS p¼0.0155; OS p¼0.0248;
Fig. 2B).–Meier curves of (A) PFS (left) and OS (right) in patients with CRC based on CAIX
tients with CRC based on the presence of stromal HKII staining. Ticks indicate right-
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and outcome
Intense stromal HKII staining was present in at least 1 of
5 images in 30 of the 60 samples analyzed (shown by arrows in
Fig. 1C). This stratiﬁcation was used to dichotomize the cases into
“stromal positive” and “stromal negative”. Stromal HKII staining
not statistically associated with sex, age at diagnosis, histological
grade, TNM stage, nor primary tumor size. Stromal HKII staining
was associated with reduced median survival duration of CRC
patients (PFS p¼0.0485; OS p¼0.0235; Fig. 2C).4. Discussion
The results of this study revealed that low HKII scoring was
associated with shorter progression-free and overall survival in
human CRC patients. During hepatocellular carcinogenesis, the
normal expression of HKIV in the liver is silenced whereas HKII
gene expression is induced, thereby promoting the glycolytic
phenotype [21]. The impact of ischemia on the metabolic pheno-
type of solid tumors is poorly understood, so we initially veriﬁed
the correlation between low oxygen conditions and the induction
of CAIX expression (a marker of tissue ischemia [15]) by exposing
human CRC cells to anoxia in vitro.
Upregulation of CAIX expression under low oxygen conditions
has been reported in breast and prostate cancer [22,23]. Signiﬁcant
correlation between HKII and has also been reported in hepato-
cellular and gastric carcinoma tissues [11,24]. However, those
studies did not examine HKII expression within different tumor
microenvironments. The abnormal vasculature that develops as a
result of tumor progression leads to ischemic areas that consist of
both hypoxic and hypoglycemic conditions [13]. While the effects
of hypoxia on tumor progression have been well documented, the
effects of hypoglycemia have been less studied. Our results reveal
that HKII staining was present primarily in non-ischemic regions
of these CRC tumors. This suggests that while hypoxia and hy-
poglycemia may have opposite effects on HKII expression, the
availability of glucose to cancer cells may ultimately determine the
expression of this enzyme, and potentially affect CRC progression
[25–28].
A number of studies have shown that hypoxia-related over-
expression of CAIX in the tumor is associated with poor survival
rates, including esophageal cancer [29], endometrioid ovarian
cancer [30], and oral cavity squamous cell carcinoma [31]. CAIX is
generally upregulated in the tumor compared to normal intestinal
epithelium [32–34]. In the present study, CAIX expression was
found to be signiﬁcantly associated with patient age and no other
clinicopathological characteristics, although high CAIX expression
was associated with a trend for shorter PFS and OS in our patient
set (HR¼0.5729 and 0.4234, respectively).
Increased HKII expression has been observed via im-
munohistochemistry when comparing hepatocellular carcinoma
to non-dysplatic cirrhosis [35]. HKII is a potential prognostic
marker in breast carcinoma [8], laryngeal squamous cell carcinoma
[9], glioblastoma multiforme [10], and gastric adenocarcinoma
[13]. In the present study, we hypothesized that high HKII ex-
pression would correlate with worse patient outcome (as has been
previously reported for CRC [12]), due to an increased capacity for
increased glucose consumption and generation of necessary gly-
colytic intermediates to sustain rapid proliferation. HKII expres-
sion was not associated with any of the patient clinicopathological
characteristics assessed. However, lower HKII expression was
found to be signiﬁcantly associated with shorter PFS and worse OS.
While ours is the ﬁrst such observation in colorectal cancer, this
correlation has also been reported in pancreatic cancer [36].The conﬂicting reports on the impact of HKII expression on
cancer progression could be reﬂected by differences in cell com-
partments within solid tumors. We found intense HKII staining in
the stroma of 50% of the cases in our study, which was associated
with worse outcome. It has become increasingly apparent that the
tumor microenvironment plays a critical role in tumorigenesis.
Stratiﬁcation of colon cancer patients based on tumor stroma re-
vealed a correlation between patients with high stromal content
and PFS and OS [37]. Stromal ﬁbroblasts that undergo myoﬁbro-
blast differentiation lose caveolin 1 (Cav-1) expression which in-
duces a cancer-associated ﬁbroblast phenotype, characterized by
an increase in glycolysis [38]. This observation is termed the ‘re-
verse Warburg effect’ and involves metabolic coupling between
supporting glycolytic stromal cells and oxidative tumor cells. Loss
of stromal Cav-1 expression was associated with both shorter
disease-free and overall survival in CRC [39]. Cav-1 null stromal
cells also upregulate key glycolytic genes, including HKII [38].
The association between poor outcome and stromal HKII ex-
pression reported here is novel for CRC and indicates the possi-
bility that the reverse Warburg effect is occurring in some pa-
tients. Stromal HKII may thus be a more informative prognostic
marker than overall HKII expression. Further study with a larger
number of patients is needed to conﬁrm these ﬁndings, and ad-
ditional studies are also needed to identify which stromal cell type
(s) are expressing HKII, and whether that expression is associated
with changes in Cav-1 as shown previously [38].
The retrospective nature of this study is a major limitation, due
to possible confounding factors and bias associated with case se-
lection. The samples for this study were gathered from different
tumor bank sites around Ontario, and difference in ﬁxation pro-
tocols may have led to variability in staining outcome. The sample
size is relatively small, and the CRC population examined is het-
erogeneous, hence prognostic effect may vary by AJCC-TNM stage.
We therefore evaluated the inﬂuence of our biomarkers on PFS
and OS in early stage (AJCC-TNM 1–3) and late stage (AJCC-TNM 4)
cases. Neither CAIX nor HKII showed a prognostic effect with
AJCC-TNM stage. However, positive Stromal HKII was signiﬁcantly
associated with both worsened PFS (p¼0.0318; HR¼3.54) and OS
(p¼0.0189; HR¼7.97) in early stage disease.
In conclusion, HKII is expressed in non-ischemic regions of CRC
tumors and lower expression by neoplastic cells is associated with
worse outcome in patients with colorectal cancer. HKII was also
highly expressed in stromal cells of some cases, where it was as-
sociated with worse outcome, suggesting an important role for
HKII in glycolytic stromal cells. Until recently, the Warburg effect
phenomenon was thought to occur in most cancer cells [40]. There
is now a growing appreciation of the complexity of tumor meta-
bolism and the interplay between the cancer cells and adjacent
stromal tissue [38]. These ﬁndings may be widely applicable, as
many different cancer subtypes exhibit an increased glycolytic
phenotype and in many cases a large proportion of the tumor mass
is stromal in nature.5. Clinical practice points
Effective biomarkers are required for correct risk stratiﬁcation
of colon cancer patients. In this study, low overall HKII expression
was associated with poor prognosis, both PFS and OS. However,
the presence of stromal HKII staining was especially associated
with poor prognosis. These results highlight the inﬂuence of tu-
mor microenvironment on cancer metabolism. Better under-
standing of the interactions between cancer cells and adjacent
stromal cells is required to determine suitable biomarkers, and our
pilot study suggests HKII has potential use in clinical practice for
risk classiﬁcation, especially in AJCC-TNM early stage patients.
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